Net prices of new antiobesity medications
Authors' conclusion
The magnitude of manufacturer discounts underscores the need to consider net price information in studies that inform private and public payers' decision-making around coverage of GLP1s for obesity.
Study context
- Population
- GLP-1 RA products (antiobesity and T2D); manufacturer discounts estimated as gross sales at list price minus manufacturer-reported revenue, less government program discounts (340B, Medicaid, Medicare Part D coverage gap)
- Comparison
- GLP1s approved for obesity vs GLP1s approved for T2D
- Outcome
- Net prices of GLP1s after manufacturer discounts
Methodological detailspeer-reviewed estimation method
- Peer-reviewed estimation method
Main finding
As reported in the abstract
| Group | Value | Net price per month of supply |
|---|---|---|
| GLP1s approved for obesity | 41% | $717 to $761 |
| GLP1s approved for T2D | 54% to 59% | $312 to $469 |
Value
GLP1s approved for obesity41%
GLP1s approved for T2D54% to 59%
Net price per month of supply
GLP1s approved for obesity$717 to $761
GLP1s approved for T2D$312 to $469
Original publication
Net prices of new antiobesity medications. Obesity (Silver Spring). Published 16 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →